WA-based medicinal cannabis company Zelira Therapeutics has signed an exclusive manufacturing deal with Tasmania Alkaloids (TasAlk) to produce its insomnia product ZLT-101 following a successful human trial.
The world-first trial at the University of WA’s Centre for Sleep Science, involving 23 patients with chronic insomnia, found those using ZLT-101 reported longer, deeper sleep, better quality of life and lower levels of stress and fatigue. Only minor, temporary side effects – dry mouth and headache – were reported.
Zelira hopes to have the treatment available for patients under its Insomnia brand before the end of the year.
Under the agreement, TasAlk will have exclusive rights to manufacture Zelira’s Insomnia and Hope medicinal cannabis products in AsiaPac for the first year and then on a semi-exclusive basis for the next three years.
Hope was developed in the US as a treatment for autism.
Zelira managing director Dr Richard Hopkins said: “The agreement reaffirms our commitment to bring our clinically validated products to market in 2020.”
TasAlk CEO Ross Murdoch said: “This agreement aligns with our business model and expertise in providing clinical trial materials. It provides the foundation for a long-term partnership that has potential to open up supply opportunities in major world markets for Zelira’s products.”